Newsletters

‹ Back

Beyond Benchmark Scores: Clinical Integration and Real-World Evidence

ELHS Monthly Newsletter (May 2026)

Paving the Way for Global Health Equity with Generative AI and Learning Health Systems

Subscribe | All Issues

 

 

Dear Friends,

This month’s progress reflects a major transition in healthcare AI: from isolated prediction tools toward clinically integrated, continuously evaluated, and workflow-aware systems. Across policy, clinical reasoning, cancer screening, molecular medicine, and clinical documentation, the field is rapidly moving beyond proof-of-concept demonstrations toward large-scale implementation and real-world accountability.

 

 

Several studies highlighted the growing capability of multimodal and reasoning-based AI systems. New evidence showed that conversational multimodal diagnostic AI can integrate text, images, ECGs, and clinical documents with performance surpassing physicians in simulated telehealth consultations. At the same time, benchmarking studies confirmed that differential diagnosis remains one of the most difficult challenges for current large language models, reinforcing the need for careful human oversight and prospective clinical validation. Importantly, randomized trials demonstrated that collaborative clinician-AI workflows improved diagnostic accuracy, supporting the emerging view that AI functions best as a clinical teammate rather than a replacement for physicians.

A strong theme across recent publications is the need for new governance and evidence frameworks. Policy leaders proposed licensure models for autonomous clinical AI, while multiple editorials emphasized that claims of AI benefit must be supported by rigorous, continuously monitored clinical evidence. Researchers also warned that adaptive AI systems embed hidden value judgments into clinical workflows, making transparency, institutional accountability, and multidisciplinary oversight essential for safe deployment. These discussions signal that healthcare AI is entering a new phase where evaluation science, implementation science, and regulatory science are becoming as important as model performance itself.

Clinical implementation studies also demonstrated tangible operational impact. AI-powered scribes reduced documentation burden and EHR time across major academic medical centers, while national lung cancer screening programs illustrated how AI-enabled infrastructure can scale population health interventions and improve early detection, especially in underserved communities. Emerging deep learning risk models for breast cancer screening further suggested that AI may support more precise and equitable screening strategies than traditional criteria alone.

Beyond clinical workflows, advances in biological AI and multi-omics integration point toward the long-term vision of patient-specific digital twins and AI systems capable of modeling the “language of life” across DNA, RNA, proteins, and cellular systems. These developments suggest that the convergence of generative AI, multimodal reasoning, molecular medicine, and learning health systems is accelerating rapidly.

Taken together, this month’s progress reinforces a central message: the future of healthcare GenAI will not be determined solely by larger models or higher benchmark scores, but by whether health systems can responsibly integrate AI into real-world clinical learning environments that continuously improve care quality, diagnostic accuracy, operational efficiency, and health equity.       

Below, I discuss with my ChatGPT copilot the emerging challenges and opportunities in clinical integration and evidence generation for healthcare GenAI. Please read on.

 

Warm regards,
AJ

AJ Chen, PhD
Founder & PI, ELHS Institute
Silicon Valley, USA
https://elhsi.org/Newsletters
https://elhsi.com

 

~

 

From Page Mill

(Recent papers, news, and events showcasing the progress of GenAI and LHS) 

Show us the evidence for the value of medical AI. Nat Med. 2026 Apr;32(4):1163. doi:10.1038/s41591-026-04389-4.

[2026/4 editorial] Claims that medical AI is improving care must be backed by appropriate evidence. A framework for how AI medical technologies should be evaluated, by what metrics and against which benchmarks is urgently needed. Without clearer rules and a direct mandate to provide robust evidence, the threshold for claiming value remains too variable. Going forward, the medical AI field must develop a consistent framework to connect claims of clinical value of an AI tool to the appropriate type of evidence needed to support those claims. Moreover, because model performance may shift over time, post-deployment monitoring should be seen as an institutional expectation rather than as a late, optional addition. The next phase of progress will depend not only on better models and new applications but also on clearer expectations for how clinical impact is defined, evaluated and communicated.

 

Baicker K, Obermeyer Z. AI Will Accelerate Drug Discovery by Accelerating Clinical Evidence. JAMA Health Forum. 2026;7(4):e261596. doi:10.1001/jamahealthforum.2026.1596

[2026/4] The AI revolution will surely dramatically accelerate medical discovery. But protein folding and molecular design alone will not get new treatments to patients without fixing the longest lags: enrolling and evaluating clinical trials. Despite important caveats, the use of AI for clinical trials—predictions to speed and better target enrollment, generate finely calibrated outcomes from readily available data, and determine safety and efficacy over shorter time horizons—can reduce costs, accelerate innovation, and unlock huge benefits to patients.

 

Patil, S.V., Myers, C.G. & Dai, T. Protecting clinical value judgment in the age of AI. npj Digit. Med. 9, 269 (2026). 

[2026/3] Adaptive AI systems embedded in clinical decision-making workflows operationalize hidden value tradeoffs at scale, generating distinct liability pressures and constraining clinicians’ ability to weigh and choose among competing value priorities. To redirect attention from technical model design to procurement and implementation accountability, we propose a collaborative framework: federal mandates for standardized transparency via Model Cards, paired with internal, multidisciplinary institutional reviews to deliberate and document value-laden configurations.

 

Bergman A, Wachter RM, Emanuel EJ. A Licensure Framework for Autonomous Clinical AI. JAMA. Published online April 29, 2026. doi:10.1001/jama.2026.5483

[2026/4] Existing regulatory frameworks for clinical AI are ill suited to adaptive, general-purpose systems. Instead, a licensure-based approach, grounded in ongoing clinical evaluation, offers a safer path forward. Prior proposals have suggested adapting clinician licensure models to govern clinical AI, emphasizing standardized examinations, supervised clinical use, and periodic reevaluation. We support this approach, extending it in 3 fundamental respects by (1) focusing explicitly on autonomous clinical agents; (2) grounding licensure in workforce constraints that make autonomous clinical AI not merely possible but also necessary; and (3) addressing the regulatory fragmentation already emerging across states. The developer would be accountable for model performance; the federally qualified health center leadership, including its clinicians, would be responsible for workflow integration, supervision protocols, and adverse event reporting.

 

Ong JCL, Ning Y, Liu M, et al. Innovating global regulatory frameworks for generative AI in medical devices is an urgent priority. NPJ Digit Med. 2026;9(1):364. doi:10.1038/s41746-026-02552-2.

[2026/3] The integration of generative AI (GenAI) and large language models (LLMs) in healthcare presents both unprecedented opportunities and challenges, necessitating innovative regulatory approaches. In this perspective, we discuss the risks of GenAI and LLM-based medical devices, the limitations of current medical device regulation frameworks when applied to GenAI or LLMs, and advocate for global collaboration in regulatory science research through engaging multidisciplinary expertise and focusing on the needs of diverse populations.

 

Peter G. Brodeur et al. Performance of a large language model on the reasoning tasks of a physician. Science 392,524-527(2026). DOI:10.1126/science.adz4433

[2024/4] More than 65 years ago, complex clinical diagnostic reasoning cases were introduced as the gold standard for the evaluation of expert medical computing systems, a standard that has held ever since. In this study, we report the results of a physician evaluation of a large language model (LLM) on challenging clinical cases across five experiments with a baseline of hundreds of physicians. We then report a real-world study comparing human expert and artificial intelligence (AI) second opinions in randomly selected patients in the emergency room of a major tertiary academic medical center. In all experiments, the LLM outperformed physician baselines and displayed continued improvement from prior generations of AI clinical decision support. Our study suggests that LLMs have eclipsed most benchmarks of clinical reasoning, motivating the urgent need for prospective trials.

 

Saab K, Park C, Strother T, Freyberg J, et al.  Advancing conversational diagnostic AI with multimodal reasoning. Nat Med. 2026;32(5):1726-1736. doi:10.1038/s41591-026-04371-0.

[2026/5] Here we introduce a multimodal extension of the Articulate Medical Intelligence Explorer (multimodal AMIE), capable of gathering, interpreting and reasoning about multimodal data within a diagnostic conversation. We evaluated this updated, state-aware version of multimodal AMIE against primary care physicians (PCPs) in a randomized, blinded exploratory study comprising 105 simulated telehealth consultations, which included dermatology photographs, electrocardiograms and clinical documents. As assessed by 18 specialist physicians, multimodal AMIE outperformed PCPs not only in diagnostic accuracy but also in conversation quality, including history-taking and empathy. These results validate the efficacy of state-aware reasoning in bridging the gap between text and visual information and demonstrate the potential for artificial intelligence (AI) systems to augment clinicians in complex, multimodal diagnostic settings.

 

Rao AS, Esmail KP, Lee RS, et al. Large Language Model Performance and Clinical Reasoning Tasks. JAMA Netw Open. 2026;9(4):e264003. doi:10.1001/jamanetworkopen.2026.4003

[2026/4] Can off-the-shelf large language models (LLMs) demonstrate reliable performance across the clinical workflow? In this cross-sectional study of 21 frontier LLMs tested on 29 standardized clinical vignettes, Grok 4 and other reasoning-optimized models achieved the highest scores, while Gemini 1.5 Flash performed lowest. Differential diagnosis consistently showed the weakest performance, while final diagnosis and management had stronger performances. These findings suggest that despite progress, current LLMs remain limited in early diagnostic reasoning and cannot yet be relied on for unsupervised patient-facing clinical decision-making.

 

Everett SS, Bunning BJ, Jain P, et al. From tool to teammate in a randomized controlled trial of clinician-AI collaborative workflows for diagnosis. NPJ Digit Med. 2026 Mar 18. doi:10.1038/s41746-026-02545-1.

[2026/3] We conducted a randomized controlled trial (n = 70 clinicians) to assess a custom system designed for collaborative diagnostic reasoning. The design involved independent diagnostic assessments by the clinician and AI, followed by an AI-generated synthesis integrating both perspectives, highlighting agreements, disagreements, and offering commentary. We evaluated two collaborative workflows: AI as first opinion (preceding clinician) and AI as second opinion (following clinician). Both improved clinician diagnostic accuracy over conventional resources, (85% and 82% vs. 75%). Performance was comparable across workflows and not statistically different from AI-alone accuracy (90%), highlighting the potential of collaborative AI to complement clinician expertise. Qualitative analyses illustrate how workflow design shapes human-AI interaction.

 

Spitzer, P., Hendriks, D., Rudolph, J. et al. The effect of medical explanations from large language models on diagnostic accuracy in radiology. npj Digit. Med. 9, 333 (2026).

[2026/4] We find that the format of explanations significantly influences diagnostic accuracy. The chain-of-thought explanations yielded the best performance, improving the diagnostic accuracy by 12.2% compared to the control condition without LLM support (P = 0.001). The chain-of-thought explanations are also superior to the standard output without explanation ( + 7.2%; P = 0.040) and the differential diagnosis format ( + 9.7%; P = 0.004). We further assessed the robustness of these findings across case difficulty and different physician backgrounds, such as general vs. specialized radiologists. Evidently, in the controlled setting of our vignette study, explaining the reasoning for a diagnosis helps physicians to identify and correct potential errors in LLM predictions and thus improve overall decisions. 

 

Nadkarni G, McGreevy J, Gavin N et al. From prediction to navigation for artificial intelligence in medicine. The Lancet, 2026.

[2026/4] Selecting the right action from a set of potential clinical actions requires synthesising patient characteristics, trajectory, and context, which is a cognitively demanding task in time-constrained clinical settings. Thus, what is required is a transition from predictive to navigational AI, in which we move beyond estimating risks to providing decision support for clinical actions. As clinicians use data to make decisions, these systems should support clinical judgement by highlighting actions most likely to help a particular patient at a particular time, rather than merely identifying who is at risk.

 

Lee RW, Nair A, Balata H, et al. Implementation of the NHS England Lung Cancer Screening Programme over 5 years. Nat Med. 2026;32(5):1817-1826. doi:10.1038/s41591-026-04292-y.

[2026/5] Lung cancer screening with low-dose computed tomography has been proven to reduce lung-cancer-specific and all-cause mortality. The UK launched the NHS England Targeted Lung Health Check Programme in 2019, which has now become the national Lung Cancer Screening Programme, with full coverage expected by 2030. Here we present the progress and outcomes of the program. People aged 55-74 were offered low-dose computed tomography of the thorax if they had ever smoked and if risk thresholds, as determined by multivariable models, were met. Delivery of the program is through regionally federated clinical infrastructure and leadership, with national strategic, clinical and economic frameworks. The program has invited over two million people, with 7,193 lung cancers diagnosed-63.1% at tumor, node, metastasis stage 1 and 12.6% stage 2-to March 2025. This has increased the early-stage proportion of lung cancer in England over 5 years, particularly in socioeconomically deprived regions. The NHS England Programme exemplifies how large-scale implementation can be achieved at speed through centralized protocols and effective project management. The program has demonstrated feasibility and scalability in reaching high-risk and underserved populations, but needs to further address inequalities in participation. These findings support adoption of lung cancer screening across the UK and globally, and offer practical tools for international adaptation.

 

Lamb LR, Mercaldo SF, Carney A, Lehman CD. A Deep Learning Breast Cancer Risk Model for Precise Supplemental Screening. JAMA Netw Open. 2026;9(5):e2610559. doi:10.1001/jamanetworkopen.2026.10559

[2026/5] Can a deep learning (DL) model applied to screening mammograms more accurately identify patients at risk for future breast cancer and false-negative screening results than breast density? In a multisite cohort study of 123 091 consecutive screening mammograms in 67 019 patients, the DL model showed greater accuracy than breast density in estimating future breast cancer. False-negative rates were stratified across DL risk groups and were highest in high-risk patients. Findings of this study suggest that DL risk models could offer a more precise and equitable alternative to breast density as a policy criterion for determining access to supplemental breast imaging.

 

Liu, F., Beck, S., Yang, L. et al. Advancing AI for multi-omics and clinical data integration in basic and translational cancer research. Nat Rev Cancer (2026).

[2026/4] Artificial intelligence (AI) has emerged as the essential technology to decipher these complex, high-dimensional datasets, powering substantial advances in early diagnosis, precise patient stratification, prediction of therapeutic response and the elucidation of mechanisms of drug resistance. To translate these powerful predictive models into practice, explainable AI is critical for building clinical trust and generating novel, testable biological hypotheses. While challenges in data accessibility and model generalizability persist, the field is advancing toward patient-specific digital twins, promising to simulate individual disease trajectories and optimize treatments, thereby heralding a new era of precision oncology.

 

Rao VM, Zhang S, Plosky BS, et al. Generalist biological artificial intelligence in modeling the language of life. Nat Biotechnol. 2026 Mar 20. doi:10.1038/s41587-026-03064-w.

[2026/3] Generalist biological artificial intelligence (GBAI) represents a transformative approach to modeling the ‘language of life’—the flow of information from DNA to cellular function. This Review synthesizes rapid advances in biological AI to interpret and generate DNA, RNA, proteins and cellular systems. We chart a course toward comprehensive systems that can concurrently process and predict across these domains, performing several critical biological tasks simultaneously. Substantial opportunities lie in synergizing language and structural AI, leveraging specialized models and improving AI agents for autonomous discovery. After addressing challenges in data, biological complexity, scalability and experimental validation, GBAI has the potential to deepen our understanding of disease pathways and biomarkers, advance automated therapeutic design and evaluation, and integrate within virtual cells to meaningfully simulate biological activity.

 

Rotenstein LS, Holmgren AJ, Thombley R, et al. Changes in Clinician Time Expenditure and Visit Quantity With Adoption of Artificial Intelligence–Powered Scribes: A Multisite Study. JAMA. 2026;335(16):1408–1417. doi:10.1001/jama.2026.2253

[2026/4] In 5 academic medical centers, AI scribe adoption was associated with decreases in total EHR and documentation time of 13.4 and 16.0 minutes, respectively, and an increase of 0.49 visits per week. Changes associated with AI scribe adoption were greatest for primary care specialists, advanced practice clinicians, female clinicians, and clinicians who used AI scribes in 50% or more of visits. These findings indicate initial, moderately beneficial associations of AI scribes with changes in key EHR activity measures and visit volume.

 

Kathryn A. Phillips et al. Diagnostics investments and disease burden. Science 392,151-153(2026). DOI:10.1126/science.aec0173.
[2026/4] Screening and testing for disease using “diagnostics” (see the box) is increasingly essential across global health care systems to identify and target individuals who will most benefit from health care interventions and to address unmet disease burden. However, access to diagnostics is uneven and often inadequate, particularly in lower- and middle-income countries, with an estimated 47% of the world’s population having limited or no access to diagnostics. Despite these needs, diagnostics historically have received lower investment, insurance coverage, and payment rates than drugs, creating barriers to innovation. We leverage a recent, in-depth assessment of the mismatch between drug development and disease burden in the US to address two critical gaps: (i) policies specifically relevant to diagnostics and integrated diagnostic–drug combinations, and (ii) how findings for the US extrapolate globally. We focus on underinvestment in diagnostics and explore how regulatory and payment policies could facilitate diagnostic innovation.

~

 

 

 

 

In the Eyes of GPTs

(AJ in conversation with ChatGPT to understand how machines view human healthcare)

 

 Many studies, including ours, point to the need to study the clinical integration of GenAI for specific clinical tasks such as early diagnosis of Alzheimer’s disease. What are the various integration approaches that should be tested?

 

 ChatGPT

Integration approaches that should be tested

1. AI as a first-opinion generator

The GenAI system reviews the case first and produces an initial differential diagnosis, key reasoning, and suggested next tests before the clinician forms an opinion.

This tests whether AI can broaden early diagnostic thinking, especially for complex, uncommon, or rare diseases. The risk is anchoring: clinicians may over-trust the AI’s first framing.

Best for testing: early diagnosis, rare disease detection, triage, missed-diagnosis reduction.

 

2. AI as a second-opinion reviewer

The clinician first documents their assessment, then AI provides alternative diagnoses, missing considerations, diagnostic gaps, and suggested confirmatory tests.

This is likely one of the safest and most practical approaches because it preserves clinician independence while using AI to challenge premature closure. It aligns well with your ELHS diagnostic gap report model and with RCT evidence comparing AI-first vs. AI-second workflows.

Best for testing: diagnostic quality improvement, complex case review, inpatient consults, outpatient unresolved symptoms.

 

3. Independent clinician-AI parallel assessment + reconciliation

Clinician and AI independently generate diagnostic assessments. A synthesis layer then compares agreement, disagreement, missing diagnoses, and evidence gaps.

This may be especially powerful because it treats AI as a “teammate” rather than a simple tool. The trial you selected used this kind of independent clinician/AI assessment followed by AI-generated synthesis of agreements and disagreements.

Best for testing: high-risk diagnosis, multidisciplinary case review, second-opinion clinics, diagnostic safety programs.

 

4. AI-generated differential diagnosis checklist

AI generates a structured differential diagnosis list organized by probability, severity, organ system, or “must-not-miss” conditions.

This approach is simple to integrate, but needs careful evaluation because long lists may increase cognitive burden or introduce false positives. The key question is whether the list improves clinically meaningful diagnostic consideration, not whether it merely contains the correct diagnosis somewhere.

Best for testing: diagnostic completeness, rare complications, RA multisystem complications, emergency medicine, primary care.

 

5. AI-generated diagnostic gap report

AI compares the current working diagnosis against the patient’s longitudinal evidence and identifies missing tests, unexplained symptoms, inconsistent findings, delayed diagnosis risks, and alternative hypotheses.

This is especially aligned with ELHS. It shifts AI from “answer generator” to gap detector, which may be safer, more explainable, and easier to integrate into clinician review.

Best for testing: delayed diagnosis, misdiagnosis prevention, persistent symptoms, chronic complex disease, health equity monitoring.

 

6. AI as test-selection and next-step advisor

Instead of asking AI to name the final diagnosis, the system recommends the next best diagnostic step: labs, imaging, referral, repeat history, or watchful waiting.

This fits the shift from prediction to “navigational AI,” where AI supports clinical action rather than only risk prediction.

Best for testing: diagnostic efficiency, unnecessary testing reduction, time-to-diagnosis, cost-value outcomes.

 

7. AI explanation formats: no explanation vs. brief rationale vs. stepwise reasoning

The same AI prediction can be integrated with different explanation formats. Evidence from radiology suggests explanation format can significantly affect physician accuracy, with stepwise reasoning improving diagnostic performance in a controlled study.

Best for testing: clinician trust calibration, error correction, overreliance, diagnostic accuracy.

 

8. AI as a real-time clinical conversation assistant

AI participates during history-taking by suggesting follow-up questions, missing symptoms, red flags, and relevant records to review.

This is more advanced but important, especially as multimodal diagnostic AI systems begin integrating images, ECGs, documents, and dialogue in simulated consultations.

Best for testing: primary care, telehealth, emergency triage, intake workflows.

 

9. AI as an asynchronous pre-visit or post-visit reviewer

The AI reviews records before the appointment or after the clinician note is completed, then generates a concise diagnostic quality review.

This may be highly feasible because it does not interrupt the encounter. It also fits learning health system workflows: review, feedback, outcome capture, and continuous improvement.

Best for testing: specialty referral preparation, chart review, diagnostic delay reduction, follow-up safety-netting.

 

10. Patient-facing AI summary + clinician-facing diagnostic report

Patients use AI to summarize their longitudinal records, symptoms, and concerns; clinicians receive a structured report highlighting key diagnostic questions and evidence gaps.

This approach may be especially important for health equity because patients with fragmented care, limited access, or persistent undiagnosed symptoms often struggle to communicate their full medical journey.

Best for testing: patient empowerment, diagnostic access, communication quality, equity in complex diagnosis.

 

 This Nature editorial provides a very practical framework for requiring different levels of evidence before claiming different levels of AI benefit in clinical care.
Nature editorial
Could you summarize its recommendations and prioritize them for the current stage of healthcare GenAI, in which real-world clinical evidence for GenAI applications is still almost completely lacking?

 

 ChatGPT

The Nature Medicine editorial, “Show us the evidence for the value of medical AI,” is important because it reframes the central problem in healthcare AI from model performance to evidence standards for clinical value claims. (Nature)

The editorial’s core argument is very practical: Different claims about AI require different levels of evidence.

This is highly relevant now because most healthcare GenAI applications are still making claims based primarily on benchmark performance, retrospective validation, physician ratings, or simulated vignette studies, while real-world prospective evidence remains extremely limited.

 

For the current stage of GenAI in healthcare, I think the editorial implicitly suggests a prioritized evidence hierarchy like this:

Practical Evidence Requirement Framework for Current Healthcare GenAI

Level 1 — Technical capability evidence

Question: Can the model technically perform the task?

Typical evidence:

• Benchmark datasets
• Retrospective validation
• NEJM CPC studies
• Multiple-choice exams
• Simulated vignettes
• Human-AI comparisons

Appropriate claims:

• “The model can generate differential diagnoses.”
• “The model achieved X accuracy.”
• “The model performs comparably to physicians under controlled conditions.”

NOT enough to claim: improved patient outcomes, improved safety, workflow benefit, or health system value.

The editorial clearly argues that the field is currently over-claiming at this level.

 

Level 2 — Workflow integration evidence

Highest priority RIGHT NOW

Question: Can clinicians realistically integrate the AI into routine workflows?

What should be studied:

• AI-first vs AI-second workflows
• Diagnostic gap reports
• Independent clinician-AI review
• Explanation formats
• Timing of AI delivery
• Human-AI disagreement handling
• Alert burden
• Clinician trust calibration

Outcomes: clinical integration rate, diagnostic consideration changes, workflow disruption, usability, cognitive burden, physician adoption, trust, time efficiency.

This is probably the most urgent evidence gap in healthcare GenAI today.

The editorial emphasizes that even technically strong systems may fail clinically because outputs are: poorly timed, hard to interpret, inconsistently acted upon, or disruptive to workflows.

This directly supports your argument that integration approaches themselves must become research objects.

 

Level 3 — Decision influence evidence

Second highest priority

Question: Does AI actually change clinician decisions?

What should be measured:

• change in differential diagnosis,
• additional tests ordered,
• earlier referrals,
• reduction in missed diagnoses,
• changed management plans,
• escalation/de-escalation decisions.

Key insight:

This is different from “AI accuracy.”

A highly accurate AI that clinicians ignore has no clinical value.

Conversely, a moderate AI system that consistently helps clinicians reconsider overlooked diagnoses may create substantial value.

Your RA complication study is already operating at this level: physicians integrated AI hypotheses into diagnostic reasoning, and prospective cases showed AI influenced final diagnoses.

This is exactly the kind of evidence the editorial argues is currently lacking.

 

Level 4 — Real-world clinical outcome evidence

Gold standard but still rare

Question: Does AI improve actual patient outcomes?

Outcomes: earlier diagnosis, mortality, morbidity, complication reduction, hospitalizations, patient-reported outcomes, quality of life, diagnostic delay, healthcare utilization.

Required study designs:

• prospective studies,
• pragmatic trials,
• embedded LHS studies,
• cluster randomized trials,
• continuous monitoring.

The editorial strongly argues that healthcare AI must ultimately be evaluated like other medical interventions: not merely by prediction accuracy, but by demonstrated clinical benefit.

But the field is mostly not here yet.

 

Level 5 — Health system and equity evidence

Probably the next frontier

Question: Does AI improve healthcare systems at scale?

Outcomes: equity, access, diagnostic disparities, clinician burnout, workforce augmentation, cost-effectiveness, scalability, population-level impact.

This is especially important because AI may: reduce disparities, preserve disparities, or amplify disparities.

Recent studies already show that LLMs may recommend different care based on socioeconomic context. (Reuters)

This is where your ELHS framework becomes highly important: continuous learning + equity metrics + prospective monitoring.

 

My prioritization for the CURRENT stage of healthcare GenAI

Immediate priorities (2026–2028)

1. Workflow integration studies

Most important immediate gap.

We still do not know where AI should enter workflows, how clinicians should interact with it, how disagreements should be handled, how explanations affect reasoning, and which integration model is safest.

2. Decision influence studies

Second priority.

Need evidence that AI changes real clinician decisions in beneficial ways.

This is likely the most feasible bridge between benchmark studies and patient outcome trials.

3. Continuous real-world monitoring

Critical because GenAI systems evolve over time.

Static retrospective validation is insufficient for adaptive AI.

LHS-style continuous evaluation may become essential infrastructure.

4. Equity-aware evaluation

Must begin early, not later.

Equity should become a monitored outcome, not merely an ethical discussion.

5. Large outcome trials

Necessary eventually, but probably premature for many current GenAI tools.

The field first needs stable workflows, integration standards, evaluation metrics, and clearer task definitions.

 

The most important conceptual shift

The editorial is fundamentally saying: “Performance” is not “value.”

And for GenAI, value emerges only after integration into workflows, clinician interaction, decision influence, longitudinal monitoring, and real-world implementation.

That is why benchmark-centric evaluation is no longer sufficient for healthcare GenAI. (Nature)

 

~

 

🔹 ELHS Institute Resources 🔹

🤖 ELHS GenAI Platform

🌐 ELHS Institute Website

📰 ELHS Monthly Newsletters

▶️ ELHS Videos

👉 For Clinical AI technology support, contact us at support@elhsi.org 📩

 

~ the end ~